RxDoctor Payments Data

Jared Hollinger, MD

Neuromuscular Medicine · Huntington, WVNPI 1861871097

Payments from drug & device makers

$2,207in general payments, 2019–2025

Across 144 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$880
  • Argenx US, Inc.$486
  • UCB, Inc.$161
  • Neurelis, Inc.$153
  • Merz Pharmaceuticals, LLC$86
  • Neurocrine Biosciences, Inc.$71
  • plus $371 from 11 others

What the payments were for

  • Food & beverage$2,08294%
  • Education$1256%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$46,241
Medicare patients
222
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone33$475,395
VyvgartEfgartigimod Alfa-Fcab11$316,378
OctagamImmun Globg(Igg)/Malt/Iga Ov5018$200,818
Gamunex-CImmune Globul G/Gly/Iga Avg 4628$129,224
Pyridostigmine Bromide71$4,535
Mycophenolate Mofetil35$3,589
Riluzole30$2,358
Pregabalin39$2,102
Azathioprine12$1,607
Baclofen33$1,385
Gabapentin113$1,286
Carbamazepine13$659
Carbidopa-LevodopaCarbidopa/Levodopa22$516
Prednisone107$472
Duloxetine Hcl21$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$486$316,37811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuromuscular medicine providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other neuromuscular medicine in Huntington

Where these figures come from

Is this you, or does something look wrong? →